These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
272 related items for PubMed ID: 25052539
1. An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab. Akaike K, Suehara Y, Takagi T, Kaneko K, Saito T. Skeletal Radiol; 2014 Dec; 43(12):1767-72. PubMed ID: 25052539 [Abstract] [Full Text] [Related]
2. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence? Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, Franchi A, Capanna R, Campanacci DA. Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015 [Abstract] [Full Text] [Related]
3. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint. Duan DK, Zhang GC, Sun BJ, Ma TX, Zhao M. Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478 [Abstract] [Full Text] [Related]
4. The clinical approach toward giant cell tumor of bone. van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovée JV, Hogendoorn PC, Gelderblom H. Oncologist; 2014 May; 19(5):550-61. PubMed ID: 24718514 [Abstract] [Full Text] [Related]
5. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone. Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC. Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217 [Abstract] [Full Text] [Related]
6. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone. Ud Din N, Umer M, Park YK. Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739 [Abstract] [Full Text] [Related]
7. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T. J Orthop Surg (Hong Kong); 2020 Dec; 28(2):2309499020929786. PubMed ID: 32539628 [Abstract] [Full Text] [Related]
8. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R. World J Surg Oncol; 2016 Nov 04; 14(1):281. PubMed ID: 27809843 [Abstract] [Full Text] [Related]
9. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study. Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T. BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567 [Abstract] [Full Text] [Related]
10. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists. Tariq MU, Umer M, Khan Z, Saeed J, Siddiqui MA, Din NU. Ann Diagn Pathol; 2020 Apr 22; 45():151479. PubMed ID: 32088577 [Abstract] [Full Text] [Related]
11. The role of Denosumab in joint preservation for patients with giant cell tumour of bone. Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS. Bone Joint J; 2021 Jan 22; 103-B(1):184-191. PubMed ID: 33380180 [Abstract] [Full Text] [Related]
12. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report. Tang Q, Lu J, Zhu X, Song G, Wu H, Xu H, Wang A, Wang J. Eur Spine J; 2023 Dec 22; 32(12):4297-4305. PubMed ID: 37318598 [Abstract] [Full Text] [Related]
13. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS. Eur J Cancer; 2016 May 22; 59():1-12. PubMed ID: 26990281 [Abstract] [Full Text] [Related]
14. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience. Agarwal MG, Gundavda MK, Gupta R, Reddy R. Clin Orthop Relat Res; 2018 Sep 22; 476(9):1773-1782. PubMed ID: 30794215 [Abstract] [Full Text] [Related]
15. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone]. Sørensen AL, Hansen RL, Jørgensen PH. Ugeskr Laeger; 2016 Sep 05; 178(36):. PubMed ID: 27593237 [Abstract] [Full Text] [Related]
16. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy. Yonezawa N, Murakami H, Kato S, Takeuchi A, Tsuchiya H. Eur Spine J; 2017 May 05; 26(Suppl 1):236-242. PubMed ID: 28396950 [Abstract] [Full Text] [Related]
17. Giant cell tumour of bone in the denosumab era. van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H. Eur J Cancer; 2017 May 05; 77():75-83. PubMed ID: 28365529 [Abstract] [Full Text] [Related]
18. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I. Clin Cancer Res; 2012 Aug 15; 18(16):4415-24. PubMed ID: 22711702 [Abstract] [Full Text] [Related]
19. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center. Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W. J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187 [Abstract] [Full Text] [Related]
20. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS. Clin Orthop Relat Res; 2020 Nov 17; 478(11):2522-2533. PubMed ID: 32401001 [Abstract] [Full Text] [Related] Page: [Next] [New Search]